{"log_id": 4095095316794555083, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.00039, "average": 0.974115, "min": 0.954356}, "location": {"width": 59, "top": 182, "height": 31, "left": 1454}, "words": "品监"}, {"probability": {"variance": 0.060628, "average": 0.751447, "min": 0.50522}, "location": {"width": 57, "top": 232, "height": 29, "left": 1445}, "words": "生证"}, {"probability": {"variance": 0.028696, "average": 0.905748, "min": 0.368455}, "location": {"width": 1155, "top": 271, "height": 91, "left": 374}, "words": "伊曲康唑主要在肝脏代谢成多种机谢产物经体外试验显示,cYP3A是参与伊曲康唑代谢骑"}, {"probability": {"variance": 0.015022, "average": 0.935408, "min": 0.38685}, "location": {"width": 1064, "top": 354, "height": 57, "left": 322}, "words": "的主要酶,主要代谢产物为羟基伊曲康哇,该产物在体外试验中显示了与伊康唑相当的抗真菌"}, {"probability": {"variance": 0.021826, "average": 0.930907, "min": 0.520503}, "location": {"width": 461, "top": 415, "height": 47, "left": 322}, "words": "活性,其血浆浓度谷值为原形药物的2倍"}, {"probability": {"variance": 0.024148, "average": 0.84333, "min": 0.687935}, "location": {"width": 54, "top": 477, "height": 29, "left": 374}, "words": "排泄"}, {"probability": {"variance": 0.019859, "average": 0.937771, "min": 0.380749}, "location": {"width": 1014, "top": 504, "height": 59, "left": 376}, "words": "静脉给药后,约为剂量1%以下的伊曲康唑及其活性代谢物羟基伊曲康唑经肾脏泄口服"}, {"probability": {"variance": 0.013122, "average": 0.952544, "min": 0.438728}, "location": {"width": 1066, "top": 555, "height": 59, "left": 322}, "words": "给予的伊曲康唑后,经便排泄的原形药物约为剂量的3-18%口服给药一周内,伊曲主要"}, {"probability": {"variance": 0.008601, "average": 0.947595, "min": 0.623574}, "location": {"width": 646, "top": 616, "height": 47, "left": 326}, "words": "以无活性的代谢产物经尿(约35%)和粪便(约54%)排"}, {"probability": {"variance": 9e-06, "average": 0.99698, "min": 0.991892}, "location": {"width": 109, "top": 678, "height": 31, "left": 379}, "words": "特殊人群"}, {"probability": {"variance": 0.049134, "average": 0.854617, "min": 0.415062}, "location": {"width": 130, "top": 730, "height": 31, "left": 376}, "words": "肝害患者"}, {"probability": {"variance": 0.013283, "average": 0.94236, "min": 0.459617}, "location": {"width": 1011, "top": 756, "height": 61, "left": 383}, "words": "尚未进行肝损害患者使用本品的研究,伊曲康唑绝大部分在肝脏代谢。12例肝硬化患者和6"}, {"probability": {"variance": 0.006095, "average": 0.966437, "min": 0.644571}, "location": {"width": 765, "top": 815, "height": 52, "left": 326}, "words": "例健康志愿者年剂量口服100mg伊曲康唑胶囊,对以上两组患者的C"}, {"probability": {"variance": 0.023467, "average": 0.906389, "min": 0.49413}, "location": {"width": 239, "top": 808, "height": 34, "left": 1153}, "words": "UC和尹曲康唑的半衰"}, {"probability": {"variance": 0.016275, "average": 0.936056, "min": 0.413956}, "location": {"width": 1066, "top": 856, "height": 61, "left": 326}, "words": "期进行对比,肝硬化患者的平均Ca显著下降(下降47%),平均消除半衰期长于肝功能正常者"}, {"probability": {"variance": 0.026964, "average": 0.923292, "min": 0.383142}, "location": {"width": 1057, "top": 904, "height": 66, "left": 335}, "words": "(分别为37和16小时),根据AIC值肝硬化惠者和健康志愿者伊曲康唑的总暴露量相似,尚"}, {"probability": {"variance": 0.001889, "average": 0.965275, "min": 0.835375}, "location": {"width": 431, "top": 973, "height": 43, "left": 331}, "words": "无肝硬化患者长期使用伊曲唑的数据"}, {"probability": {"variance": 0.000687, "average": 0.976008, "min": 0.938969}, "location": {"width": 82, "top": 1032, "height": 31, "left": 379}, "words": "肾损害"}, {"probability": {"variance": 0.008452, "average": 0.944458, "min": 0.631814}, "location": {"width": 650, "top": 1064, "height": 54, "left": 386}, "words": "经静脉给药的伊曲康唑少部分(<1%)以原形药物经尿排泄"}, {"probability": {"variance": 0.014591, "average": 0.921539, "min": 0.511361}, "location": {"width": 712, "top": 1114, "height": 54, "left": 386}, "words": "单剂量静詠给药后,伊曲康在轻度(CrC150-79nl/mi"}, {"probability": {"variance": 0.019804, "average": 0.89964, "min": 0.483295}, "location": {"width": 219, "top": 1110, "height": 31, "left": 1176}, "words": "中度(CrC120-49"}, {"probability": {"variance": 0.015756, "average": 0.911967, "min": 0.580723}, "location": {"width": 306, "top": 1180, "height": 36, "left": 335}, "words": "m/min)、重度(CrCl<20"}, {"probability": {"variance": 0.022879, "average": 0.931006, "min": 0.366513}, "location": {"width": 632, "top": 1155, "height": 54, "left": 751}, "words": "肾损害患者体内的平均半衰期与康受试者相似(肾损"}, {"probability": {"variance": 0.005444, "average": 0.966541, "min": 0.655955}, "location": {"width": 1071, "top": 1206, "height": 66, "left": 328}, "words": "患者平均值的范围为42-49小时:健康受试者为48小时),根据ALC值,中度和重度损害患"}, {"probability": {"variance": 0.00676, "average": 0.962343, "min": 0.642584}, "location": {"width": 676, "top": 1267, "height": 52, "left": 331}, "words": "者伊曲康唑的总暴露量与肾功能正常者相比约下降30%和40"}, {"probability": {"variance": 0.014556, "average": 0.936152, "min": 0.563092}, "location": {"width": 1014, "top": 1306, "height": 63, "left": 388}, "words": "尚无肾损害患者长期使用伊曲康唑的数据。血液透析对伊曲康唑和羟基伊曲康唑的半衰期和"}, {"probability": {"variance": 8e-06, "average": 0.996327, "min": 0.991207}, "location": {"width": 157, "top": 1384, "height": 31, "left": 331}, "words": "清除率无影响"}, {"probability": {"variance": 0.02349, "average": 0.872808, "min": 0.549196}, "location": {"width": 459, "top": 1420, "height": 47, "left": 383}, "words": "羟丙基一B一环糊精(HP-β-CD"}, {"probability": {"variance": 0.017096, "average": 0.948814, "min": 0.391518}, "location": {"width": 1011, "top": 1454, "height": 61, "left": 390}, "words": "本品的辅料羟丙基一一环糊精在肾功能正常者体内的半衰期较短,为12小时,且持续"}, {"probability": {"variance": 0.014251, "average": 0.938978, "min": 0.497863}, "location": {"width": 1046, "top": 1505, "height": 63, "left": 333}, "words": "每日给药后本品无蓄积。在健康受试者和中重度背功能不全的患者体内,8g剂量的羟丙基一3"}, {"probability": {"variance": 0.012798, "average": 0.948949, "min": 0.398518}, "location": {"width": 1071, "top": 1557, "height": 63, "left": 333}, "words": "环精中的大部分经尿排泄剂量静脉给予伊曲康200mg后,肾害患者羟丙基一一环糊"}, {"probability": {"variance": 0.028498, "average": 0.899109, "min": 0.447327}, "location": {"width": 1071, "top": 1603, "height": 70, "left": 335}, "words": "的清除率下降,导致其暴露量升高,轻度、中度和重度肾损害患者的半衰升分别为正常"}, {"probability": {"variance": 0.015162, "average": 0.930186, "min": 0.42981}, "location": {"width": 1068, "top": 1653, "height": 70, "left": 333}, "words": "值的2、4、6倍。此类患者接受连续给药至达稳态时,会导致羟丙基一环精的积经丙"}, {"probability": {"variance": 0.010709, "average": 0.931265, "min": 0.648303}, "location": {"width": 349, "top": 1724, "height": 45, "left": 340}, "words": "基一阝一环精可通过透析清除"}, {"probability": {"variance": 0, "average": 0.738606, "min": 0.738606}, "location": {"width": 278, "top": 1708, "height": 59, "left": 1096}, "words": "有"}, {"probability": {"variance": 0.037926, "average": 0.857732, "min": 0.527113}, "location": {"width": 86, "top": 1829, "height": 31, "left": 351}, "words": "【贮藏】"}, {"probability": {"variance": 0.011056, "average": 0.94644, "min": 0.51689}, "location": {"width": 598, "top": 1863, "height": 50, "left": 390}, "words": "伊曲康唑注射液:于25℃以下贮藏。不得拆除原包装"}, {"probability": {"variance": 0.0319, "average": 0.839963, "min": 0.503546}, "location": {"width": 216, "top": 1875, "height": 57, "left": 1114}, "words": "质量管专用章"}, {"probability": {"variance": 0.015813, "average": 0.945551, "min": 0.549583}, "location": {"width": 461, "top": 1916, "height": 47, "left": 395}, "words": "氯化钠注射液:25℃以下贮藏。不得冷冻"}, {"probability": {"variance": 4e-05, "average": 0.994581, "min": 0.983429}, "location": {"width": 162, "top": 1978, "height": 31, "left": 392}, "words": "混合后的溶液"}, {"probability": {"variance": 0.019376, "average": 0.817173, "min": 0.625154}, "location": {"width": 139, "top": 2131, "height": 50, "left": 1427}, "words": "权供存"}], "language": 3}